|Table of Contents|

A comparative analysis of the effects of SBRT and IMRT for stage I non-small cell lung cancer patients unsuitable for surgery

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2022 05
Page:
824-828
Research Field:
Publishing date:

Info

Title:
A comparative analysis of the effects of SBRT and IMRT for stage I non-small cell lung cancer patients unsuitable for surgery
Author(s):
XIONG Yaozu; TONG Yusuo; ZHOU Xilei; PAN Peng; DAI Tingting; LI Tao; YU Changhua
Department of Radiotherapy,Huai'an First People's Hospital,Jiangsu Huai'an 223001,China.
Keywords:
NSCLC; SBRT; IMRT
PACS:
R734.2
DOI:
10.3969/j.issn.1672-4992.2022.05.014
Abstract:
Objective:To retrospectiveiy compare the therapeutic effects and adverse reactions of stage I non-small cell lung cancer patients unsuitable for surgery treated with SBRT and IMRT.Methods：Retrospective analysis was performed on 45 patients with stage I non-small cell lung cancer who received SBRT or IMRT radiotherapy,including 21 patients who received SBRT and 24 patients who received IMRT.Local control rate,regional control rate,progression-free survival rate,distant metastasis control rate,tumor-specific survival rate,overall survival rate and treatment-related adverse reactions were compared between the two groups.Results：Compared with IMRT group,SBRT group significantly improved the tumor local control rate,regional control rate and progression-free survival rate.The 1-year,2-year and 3-year local tumor control rates were(100%,94.4%,63.2%) vs (87.0%,52.2%,39.1%),respectively(P=0.037).The regional control rates for 1 year,2 years and 3 years were(90.3%,63.3%,45.3%) vs (65.5%,37.4%,23.3%) respectively(P=0.041).The 1-year,2-year,and 3-year progression-free survival rates were(80.4%,48.5%,43.1%) vs (52.5%,21.9%,17.5%)(P=0.042) respectively.However,SBRT group showed no advantages in distant metastasis control rate,tumor-related survival rate and overall survival rate compared with IMRT group.The 1-year,2-year and 3-year distant transfer control rates were(85.2%,64.2%,48.1%) vs(91.4%,54.9%,41.2%)(P=0.803).1-year,2-year,and 3-year overall survival rates were(95.2%,81.0%,61.9%) vs (95.8%,83.3%,66.7%)(P=0.735),respectively.The 1-year,2-year,and 3-year tumor-specific survival rates were(100%,89.5%,68.4%) vs (100%,90.9%,72.7%)(P=0.75),respectively.During the treatment period,there was no significant difference in treatment related adverse reactions between the two groups.Conclusion：In radiotherapy for stage I NSCLC,SBRT has the advantages of improving local control rate,regional control rate and progression-free survival rate compared with IMRT,but there is no significant difference in distant metastasis control rate and tumor-related survival rate and overall survival rate.The clinician can choose the appropriate radiotherapy method according to the different conditions of the patient.

References:

[1]SHINDE A,LI R,KIM J,et al.Stereotactic body radiation therapy(SBRT) for early-stage lung cancer in the elderly ［J］.Semin Oncol,2018,45(4):210-219.
[2]TANDBERG DJ,TONG BC,ACKERSON BG,et al.Surgery versus stereotactic body radiation therapy for stage I non-small cell lung cancer:A comprehensive review［J］.Cancer,2018,124(4):667-678.
[3]SCOTTI V,BRUNI A,FRANCOLINI G,et al.Stereotactic ablative radiotherapy as an alternative to lobectomy in patients with medically operable stage I NSCLC:A retrospective,multicenter analysis［J］.Clin Lung Cancer,2019,20(1):e53-e61.
[4]LI C,WANG L,WU Q,et al.A meta-analysis comparing stereotactic body radiotherapy vs conventional radiotherapy in inoperable stage I non-small cell lung cancer［J］.Medicine(Baltimore),2020,99(34):e21715.
[5]MIX M,TANNY S,NSOULI T,et al.Outcomes following stereotactic body radiotherapy with intensity-modulated therapy versus three-dimensional conformal radiotherapy in early stage non-small cell lung cancer［J］.Lung Cancer(Auckl),2019,10:151-159.
[6]BARTE JA,POWELL CA,WISNIVESKY JP,et al.Global epidemiology of lung cancer ［J］.Annals of Global Health,2019,85(1):1-16.
[7]GONZALO VARELA,NURIA M.Novoa.Definitive radiation for early stage lung cancer:Who is medically inoperable［J］.Annals of Translational Medicine,2019,7(Suppl 8):S361-375.
[8]ETTINGER DS,WOOD DE,AISNER DL,et al.Non-small cell lung cancer,version 5.2017,NCCN clinical practice guidelines in oncology［J］.J Natl Compr Canc Netw,2017,15:504-535.
[9]GIAJ-LEVRA N,BORGHETTI P,BRUNI A,et al.Current radiotherapy techniques in NSCLC:challenges and potential solutions［J］.Expert Rev Anticancer Ther,2020,20(5):387-402.
[10]DIWANJI TP,MOHINDRA P,VYFHUIS M,et al.Advances in radiotherapy techniques and delivery for non-small cell lung cancer:benefits of intensity-modulated radiation therapy,proton therapy,and stereotactic body radiation therapy［J］.Transl Lung Cancer Res,2017 Apr,6(2):131-147.
[11]VIDETIC GM,PAULUS R,SINGH AK,et al.Long-term follow-up on NRG oncology RTOG 0915(NCCTG N0927):A randomized phase 2 study comparing 2 stereotactic body radiation therapy schedules for medically inoperable patients with stage I peripheral non-small cell lung cancer［J］.Int J Radiat Oncol Biol Phys,2019,103(5):1077-1084.
[12]刘树铮.医学放射生物学（第3版）［M］.北京：原子能出版社，2006:133-134. LIU SZ.Medical radio biology(version 3) ［M］.Beijing:Atomic Energy Press,2006:133-134.
[13]BALL D,MAI GT,VINOD S,et al.Stereotactic ablative radiotherapy versus standard radiotherapy in stage 1 non-small-cell lung cancer(TROG 09.02 CHISEL):a phase 3,open-label,randomised controlled trial［J］.Lancet Oncol,2019,20(4):494-503.
[14]BEZJAK A,PAULUS R,GASPAR LE,et al.Safety and efficacy of a five-fraction stereotactic body radiotherapy schedule for centrally located non-small-cell lung cancer:NRG oncology/RTOG 0813 trial［J］.J Clin Oncol,2019,37(15):1316-1325.
[15]REESE AS,FEIGENBERG SJ,HUSAIN A,et al.Stereotactic ablative radiotherapy(SABR):Impact on the immune system and potential for future therapeutic modulation［J］.Mol Cell Pharmacol,2013,5(1):19-25.
[16]PREZZANO KM,MA SJ,HERMANN GM,et al.Stereotactic body radiation therapy for non-small cell lung cancer:A review［J］.World J Clin Oncol,2019,10(1):14-27.
[17]CRABTREE T,PURI V,TIMMERMAN R,et al.Treatment of stage I lung cancer in high-risk and inoperable patients:comparison of prospective clinical trials using stereotactic body radiotherapy(RTOG 0236),sublobar resection(ACOSOG Z4032),and radiofrequency ablation(ACOSOG Z4033)［J］.J Thorac Cardiovasc Surg,2013,145(3):692-699.
[18]TIMMERMAN RD,HU C,MICHALSKI JM,et al.Long-term results of stereotactic body radiation therapy in medically inoperable stage I non-small cell lung cancer［J］.JAMA Oncol,2018,4(9):1287-1288.
[19]NAGATA Y,HIRAOKA M,SHIBATA T,et al.Prospective trial of stereotactic body radiation therapy for both operable and inoperable T1N0M0 non-small cell lung cancer:Japan clinical oncology group study JCOG0403［J］.Int J Radiat Oncol Biol Phys,2015,93(5):989-996.
[20]WANG J,ZHOU Z,LIANG J,et al.Intensity-modulated radiation therapy may improve local-regional tumor control for locally advanced non-small cell lung cancer compared with three-dimensional conformal radiation therapy［J］.Oncologist,2016,21(12):1530-1537.

Memo

Memo:
National Natural Science Foundation of China(No.H1617/81602118）；国家自然科学青年基金（编号：H1617/81602118）
Last Update: 2022-01-27